| Literature DB >> 32904116 |
Ronald A Navarro1, Annette L Adams2, Charles C Lin3, John Fleming4, Ivan A Garcia5, Janet Lee2, Mary Helen Black2.
Abstract
BACKGROUD: To determine patient factors that lead to treatment of meniscal tears with osteoarthritis (OA) with knee arthroscopy (KA) or physical therapy only (PT-only); and to assess differences in clinical outcomes including the time to knee arthroplasty.Entities:
Keywords: Knee arthroscopy; Meniscus tear; Osteoarthritis
Mesh:
Year: 2020 PMID: 32904116 PMCID: PMC7449858 DOI: 10.4055/cios19114
Source DB: PubMed Journal: Clin Orthop Surg ISSN: 2005-291X
Fig. 1Cohort ascertainment.
Demographics, Clinical Characteristics, Healthcare Utilization, and Medication Use
| Variable | Knee arthroscopy (n = 4,883) | Physical therapy only (n = 2,143) | Total (n = 7,026) | |
|---|---|---|---|---|
| Age (yr) | < 0.001 | |||
| 45−54 | 1,706 (35) | 586 (27) | 2,292 (33) | |
| 55−64 | 1,848 (38) | 762 (36) | 2,610 (37) | |
| 65−74 | 1,037 (21) | 550 (26) | 1,587 (23) | |
| ≥ 75 | 292 (6) | 245 (11) | 537 (8) | |
| Sex | < 0.001 | |||
| Male | 2,175 (45) | 641 (30) | 2,816 (40) | |
| Female | 2,708 (55) | 1,502 (70) | 4,210 (60) | |
| Race/ethnicity | < 0.001 | |||
| White | 2,981 (61) | 1,127 (53) | 4,108 (58) | |
| Black | 467 (10) | 317 (15) | 784 (11) | |
| Hispanic | 1,147 (23) | 505 (24) | 1,652 (24) | |
| Asian Pacific island | 197 (4) | 107 (5) | 304 (4) | |
| Other/unknown | 91 (2) | 87 (4) | 178 (3) | |
| Insurance type | < 0.001 | |||
| Commercial | 3,274 (67) | 1,265 (59) | 4,539 (65) | |
| Medicaid | 47 (1) | 25 (1) | 72 (1) | |
| Medicare | 1,275 (26) | 748 (35) | 2,023 (29) | |
| Private pay | 282 (6) | 104 (5) | 386 (5) | |
| Other | 5 (0) | 1 (0) | 6 (0) | |
| Charlson Comorbidity Index | < 0.001 | |||
| 0 | 2,700 (55) | 1,070 (50) | 3,770 (54) | |
| 1 | 1,100 (23) | 479 (22) | 1,579 (22) | |
| ≥ 2 | 1,083 (22) | 594 (28) | 1,677 (24) | |
| Smoking status | < 0.001 | |||
| Current | 352 (7) | 103 (5) | 455 (6) | |
| Former | 1,127 (23) | 472 (22) | 1,599 (23) | |
| Never | 2,979 (61) | 1,413 (66) | 4,392 (63) | |
| Missing | 425 (9) | 155 (7) | 580 (8) | |
| Outpatient visit for knee pain in year prior to tear diagnosis | < 0.001 | |||
| 0 | 1,684 (34) | 907 (42) | 2,591 (37) | |
| 1 | 1,672 (34) | 688 (32) | 2,360 (34) | |
| ≥ 2 | 1,527 (31) | 548 (26) | 2,075 (30) | |
| Physical therapy visit in year prior to tear diagnosis | < 0.001 | |||
| 0 | 2,973 (61) | 1,093 (51) | 4,066 (58) | |
| 1−4 | 1,022 (21) | 523 (24) | 1,545 (22) | |
| > 4 | 888 (18) | 527 (25) | 1,415 (20) | |
| Pharmaceutical pain management in year prior to tear diagnosis | ||||
| Patient with at least 1 NSAID | 3,059 (63) | 1307 (61) | 4,366 (62) | 0.187 |
| Patient with at least 1 knee injection | 1,017 (21) | 364 (17) | 1,381 (20) | < 0.001 |
| Patient with at least 1 narcotic | 2,336 (48) | 954 (45) | 3,290 (47) | 0.010 |
| Patient with at least 1 other pain meds | 91 (2) | 36 (2) | 127 (2) | 0.595 |
Values are presented as number (%).
NSAID: nonsteroidal anti-inflammatory drug.
Fig. 2Survival curves for knee arthroplasty and physical therapy-only groups.
Hazard Ratios
| Treatment group | Event (no) | Crude incidence* | Hazard ratio† | 95% Confidence interval |
|---|---|---|---|---|
| Knee arthroscopy | 1,396 (4,883) | 50.7 | 1.30 | 1.17−1.44 |
| Physical therapy only | 488 (2,143) | 38.8 | 1.00 | Reference |
| < 0.001 |
*Per 1,000 person-years. †Weighted, adjusted.
Outpatient Visit Utilization and Pharmaceutical Use in First Year of Follow-up for Knee Pain
| Variable | Knee arthroscopy (n = 4,883) | Physical therapy only (n = 2,143) | |
|---|---|---|---|
| Outpatient visit | 0.93 | ||
| 0 | 4,420 (96) | 1,959 (96) | |
| 1 | 129 (3) | 62 (3) | |
| 2 | 32 (1) | 16 (1) | |
| ≥ 3 | 17 (0) | 7 (0) | |
| Narcotic medication*,† | 0.62 | ||
| 0 | 2,435 (53) | 1,087 (53) | |
| 1 | 815 (18) | 378 (18) | |
| ≥ 2 | 1,348 (29) | 579 (28) | |
| Knee injection* | 0.07 | ||
| 0 | 3,714 (81) | 1,605 (79) | |
| 1 | 553 (12) | 262 (13) | |
| ≥ 2 | 331 (7) | 177 (9) |
Values are presented as number (%).
*Restricted to those with ≥ 1 year of follow-up time (95% of cohort).
†Excludes narcotic medications dispensed within 7 days of knee arthroscopy.